Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$8.76
-0.14 (-1.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $112.5M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.5B
P/E
58.4x
↑EV/EBITDA
29.5x
↑ROE
4.5%
↑Gross Margin
54.6%
↑Debt/Equity
0.14
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.4%
FCF CAGR
-16.4%
FCF margin
17.8%
FCF / Net income
2.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $924.5M · net income $81.7M · FCF $164.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $924.5M | $924.5M | $687.8M | $1.07B | $886.6M |
| Net Income | $81.7M | $81.7M | $20.5M | $253.2M | $178.2M |
| EBITDA | $156.3M | $156.3M | $91.7M | $369.5M | $278.0M |
| EPS | 0.16 | 0.16 | 0.04 | 0.55 | 0.41 |
| Gross Margin | 54.6% | 54.6% | 43.9% | 56.1% | 49.0% |
| Operating Margin | 8.9% | 8.9% | 4.6% | 29.1% | 24.7% |
| Net Margin | 8.8% | 8.8% | 3.0% | 23.7% | 20.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.14 | 0.14 | 0.29 | 0.15 | 0.60 |
| Current Ratio | 2.01 | 2.01 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $164.5M | $164.5M | $-136.1M | $112.5M | $281.4M |
| Returns | |||||
| ROE | 4.5% | 4.5% | 1.2% | 12.6% | 12.7% |
| Valuation | |||||
| P/E | 58.40 | 58.40 | 227.50 | 22.69 | 28.73 |
| EV/EBITDA | 29.48 | 29.48 | 51.46 | 14.62 | 18.81 |
| P/B | 2.45 | 2.45 | 2.64 | 2.86 | 3.65 |
| Growth & Yield | |||||
| Revenue Growth | 34.4% | 34.4% | -35.6% | 20.4% | — |
| EPS Growth | 300.0% | 300.0% | -92.7% | 35.1% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
69.4%
EPS terminal req.
$0.78
Spread vs growth
230.6%
5Y implied EPS CAGR
42.5%
EPS terminal req.
$0.94
Spread vs growth
257.5%
10Y implied EPS CAGR
25.2%
EPS terminal req.
$1.51
Spread vs growth
274.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+4.0%
Start / end P/E
211.8x → 54.8x
EPS bridge
0.04 → 0.16
Residual
-222.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.